|本期目录/Table of Contents|

[1]赵芳石 综述,张雪君,潘金彬 审校.纳米颗粒用于治疗不同阶段缺血性卒中的研究进展[J].天津医科大学学报,2023,29(03):332.
点击复制

纳米颗粒用于治疗不同阶段缺血性卒中的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年03期
页码:
332
栏目:
综述
出版日期:
2023-05-20

文章信息/Info

Title:
-
文章编号:
1006－8147（2023）03-0332-04
作者:
赵芳石1 综述; 张雪君2; 潘金彬1 审校
（1.天津医科大学总医院医学影像科，天津300052；2.天津医科大学医学技术学院，天津300270）
Author(s):
-
关键词:
卒中; 缺血性卒中; 纳米颗粒
Keywords:
-
分类号:
R453.9
DOI:
-
文献标志码:
A
摘要:
目的：缺血性卒中的死亡率和发病率居全球第二，分为4个血流动力学阶段：超急性期、急性期、亚急性期和慢性期，分别表现不同的病理生理改变。目前缺血性卒中治疗高度依赖再通疗法，治疗时间窗窄，仅限于部分患者，迫切需求新的缺血性卒中治疗方法。纳米颗粒可针对在缺血性卒中不同阶段的病理生理机制，通过携带不同粒子，作用于缺血性卒中区域，从而改善缺血性卒中产生的损伤并完成神经的修复。超急性期纳米颗粒主要针对溶栓和血脑屏障的破坏；急性期纳米颗粒在于缓解神经炎症的损伤；亚急性期和慢性期纳米颗粒主要围绕修复过程，包括血管新生和神经发生。
Abstract:
-

参考文献/References:

[1] JOHNSON C O，NGUYEN M，ROTH G A，et al. Global，regional，and national burden of stroke，1990-2016：a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurology，2019，18（5）：439-458.
[2] CAMPBELL B C V，KHATRI P. Stroke[J]. Lancet，2020，396（10244）：129-142.
[3] WANG Z D，HU T T，LIANG R Z，et al. Application of zero-dimensional nanomaterials in biosensing[J]. Front Chem，2020，8:320.
[4] DONG X Y，GAO J，SU Y J，et al. Nanomedicine for ischemic stroke[J]. Int J Mol Sci，2020，21（20）:7600.
[5] BONNARD T，GAUBERTI M，MARTINEZ DE LIZARRONDO S，et al. Recent advances in nanomedicine for ischemic and hemorrhagicstroke[J]. Stroke，2019，50（5）：1318-1324
[6] THOMAS M A，HAZANY S，ELLINGSON B M，et al. Pathophysiology，classification，and MRI parallels in microvascular disease of the heart and brain[J]. Microcirculation，2020，27（8）：e12648.
[7] PANDIT R，CHEN L Y，GOTZ J. The blood-brain barrier：physiology and strategies for drug delivery[J]. Adv Drug Deliv Rev，2020，165-166：1-14.
[8] BERNARDO-CASTRO S，SOUSA J A，BRAS A，et al. Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery[J]. Front Neurol，2020，11:594672.
[9] ABDULLAHI W，TRIPATHI D，RONALDSON P T. Blood-brain barrier dysfunction in ischemic stroke：targeting tight junctions and transporters for vascular protection[J]. Am J Physiol Cell Physiol，2018，315（3）：C343-C356.
[10] BROOKS B，EBEDES D，USMANI A，et al. Mesenchymal stromal cells in ischemic brain injury[J]. Cells，2022，11（6）:1013.
[12] ORNELLO R，DEGAN D，TISEO C，et al. Distribution and temporal trends from 1993 to 2015 of ischemic stroke subtypes asystematic review and Meta-analysis[J]. Stroke，2018，49（4）：814.
[13] CRAMER S C. Recovery after stroke[J]. Continuum （Minneapolis，Minn.），2020，26（2）：415-434.
[14] YANG Q W，HUANG Q Y，HU Z P，et al. Potential neuroprotectivetreatment of stroke：targeting excitotoxicity，oxidative stress，and inflammation[J]. Front Neuro，2019，13:1036.
[15] DE ABREU R C，FERNANDES H，MARTINS PAD，et al. Native and bioengineered extracellular vesicles for cardiovascular therapeutics[J]. Nature Rev Cardiol，2020，17（11）：685-697.
[16] WALKER S，BUSATTO S，PHAM A，et al. Extracellular vesicle-based drug delivery systems for cancer treatment[J]. Theranostics，2019，9（26）：8001-8017.
[17] MITCHELL M J，BILLINGSLEY M M，HALEY R M，et al. Engineering precision nanoparticles for drug delivery[J]. Nature Rev Drug Dis，2021，20（2）：101-124.
[18] YU Y，ZHANG F L，QU Y M，et al. Intracranial calcification is predictive for hemorrhagic transformation and prognosis after intravenous thrombolysis in non-cardioembolicstroke patients[J]. J Atheroscler Thromb，2021，28（4）：356-364.
[19] BONNARD T，GAUBERTI M，DE LIZARRONDO S M，et al. Recent advances in nanomedicine for ischemic and hemorrhagic stroke[J]. Stroke，2019，50（5）：1318-1324.
[20] ABSAR S，NAHAR K，KWON Y M，et al. Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy[J]. Pharm Res，2013，30（6）：1663-1676.
[21] HSU H L，CHEN J P. Preparation of thermosensitive magnetic liposome encapsulated recombinant tissue plasminogen activator for targeted thrombolysis[J]. J Magnetism Magnetic Materials，2017，427：188-194.
[22] VOROS E，CHO M J，RAMIREZ M，et al. TPA immobilization on iron oxide nanocubes and localized magnetic hyperthermia accelerate blood clot lysis[J]. Adv Funct Mater，2015，25（11）：1709-1718.
[23] FUKUTA T，ASAI T，YANAGIDA Y，et al. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke[J]. Faseb J，2017，31（5）：1879-1890.
[24] ISLAM Y，KHALID A，PLUCHINO S，et al. Development of brain targeting peptide based MMP-9 inhibiting nanoparticles for the treatment of brain diseases with elevated MMP-9 activity[J]. J Pharm Sci，2020，109（10）：3134-3144.
[25] MACHADO-PEREIRA M，SANTOS T，FERREIRA L，et al. Anti-inflammatory strategy for M2 microglial polarization using retinoic acid-loaded nanoparticles[J]. Mediators Inflamm，2017，2017：6742427.
[26] GENG W J，TANG H L，LUO S，et al. Exosomes from miRNA-126-modified ADSCs promotes functional recovery after stroke in rats by improving neurogenesis and suppressing microglia activation[J]. Am J Translat Res，2019，11（2）：780.
[27] AMANI H，HABIBEY R，SHOKRI F，et al. Selenium nanoparticles for targeted stroke therapy through modulation of inflammatory and metabolic signaling[J]. Sci Rep，2019，9（1）:6044.
[28] DRESANG H C，HARVEY D Y，XIE S X，et al. Genetic and neurophysiological biomarkers of neuroplasticity inform post-stroke language recovery[J]. Neurorehabil Neural Repair，2022，36（6）：371-380.
[29] SUBRAMANIYAN PARIMALAM S，BADILESCU S，SONENBERG N，et al. Lab-on-a-chip for the development of pro-/anti-angiogenicnanomedicines to treat brain diseases[J]. Int J Mol Sci，2019，20（24）：6126.
[30] KIM D H，SEO Y K，THAMBI T，et al. Enhancing neurogenesis and angiogenesis with target delivery of stromal cell derived factor-1 alpha using a dual ionic pH-sensitive copolymer[J]. Biomaterials，2015，61：115-125.
[31] DENG L N，ZHANG F，WU Y L，et al. RGD-modified nanocarrier-mediated targeted delivery of HIF-1 alpha-AA plasmid DNA to cerebrovascular endothelial cells for ischemic stroke treatment[J]. ACS Biomateri Sci Eng，2019，5（11）：6254-6264.
[32] JIAN W H，WANG H C，KUAN C H，et al. Glycosaminoglycan-based hybrid hydrogel encapsulated with polyelectrolyte complex nanoparticles for endogenous stem cell regulation in central nervous system regeneration[J]. Biomaterials，2018，174：17-30.
[33] ZHANG H X，WU J，WU J H，et al. Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice[J]. J Nanobiotechnology，2019，17（1）：29.
[34] YANG J L，ZHANG X F，CHEN X J，et al. Exosomemediated delivery of miR-124 promotes neurogenesis after ischemia[J]. Mol Ther Nucleic Acids，2017，7: 278-287.
[35] FERREIRA R，FONSECA M C，SANTOS T，et al. Retinoic acid-loaded polymeric nanoparticles enhance vascular regulation of neural stem cell survival and differentiation after ischaemia[J]. Nanoscale，2016，8（15）：8126-8137.
[36] WANG C X，LIN G，LUAN Y，et al. HIF-prolyl hydroxylase 2 silencing using siRNA delivered by MRI-visible nanoparticles improves therapy efficacy of transplanted EPCs for ischemic stroke[J]. Biomaterials，2019，197：229-243.
[37] WANG Y F，COOKE M J，SACHEWSKY N，et al. Bioengineered sequential growth factor delivery stimulates brain tissue regeneration after stroke[J]. J Controlled Release，2013，172（1）：1-11.
[38] YEMISCI M，CABAN S，GURSOY-OZDEMIR Y，et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection[J]. J Cerebral Blood Flow Metabolism，2015，35（3）：469-475.
[39] XIN H Q，WANG F J，LI Y F，et al. Secondary release of exosomesfrom astrocytes contributes to the increase in neural plasticity and improvement of functional recovery after stroke in rats treated with exosomesharvested from microRNA 133b-overexpressing multipotentmesenchymalstromal cells[J]. Cell Transplantation，2017，26（2）：243-257.
[40] LING X，ZHANG G，XIA Y，et al. Exosomes from human urine-derived stem cells enhanced neurogenesis via miR-26a/HDAC6 axis after ischaemic stroke[J]. J Cell Mol Med，2020，24（1）：640-654.

相似文献/References:

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目(81801829)
作者简介 赵芳石(1991-），女，主治医师，硕士，研究方向：神经系统纳米诊疗；通信作者：张雪君，E-mail：zhangxj@tmu.edu.cn。
更新日期/Last Update: 1900-01-01